4-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluorobenzonitrile | 1016706-76-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 4-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluorobenzonitrile
• 英文别名: 4-[(1,3-Dioxoisoindol-2-yl)methyl]-3-fluorobenzonitrile
• CAS: 1016706-76-5
• 化学式: C₁₆H₉FN₂O₂
• 分子量: 280.258
• InChiKey: PXUQHDBVKUSAKH-UHFFFAOYSA-N

物化性质

• 沸点：
  461.2±40.0 °C(Predicted)
• 密度：
  1.43±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  61.2
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluorobenzonitrile 在 盐酸羟胺 、 potassium carbonate 、 一水合肼 、 三乙胺 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 、 正丁醇 为溶剂， 反应 65.08h， 生成 tert-butyl (4-(5-ethyl-1,2,4-oxadiazol-3-yl)-2-fluorobenzyl)carbamate
  参考文献：
  名称：

  Optimization of Novel 1-Methyl-1H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber’s Pole Worm

  摘要：

  A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 mu M. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 mu M. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 mu M.

  DOI：

  10.1021/acs.jmedchem.8b01544
• 作为产物：
  描述：

  3-氟-4-甲基苯腈 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 caesium carbonate 作用下， 以 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 4-((1,3-dioxoisoindolin-2-yl)methyl)-3-fluorobenzonitrile
  参考文献：
  名称：

  Optimization of Novel 1-Methyl-1H-Pyrazole-5-carboxamides Leads to High Potency Larval Development Inhibitors of the Barber’s Pole Worm

  摘要：

  A phenotypic screen of a diverse library of small molecules for inhibition of the development of larvae of the parasitic nematode Haemonchus contortus led to the identification of a 1-methyl-1H-pyrazole-5-carboxamide derivative with an IC50 of 0.29 mu M. Medicinal chemistry optimization targeted modifications on the left-hand side (LHS), middle section, and right-hand side (RHS) of the scaffold in order to elucidate the structure-activity relationship (SAR). Strong SAR allowed for the iterative and directed assembly of a focus set of 64 analogues, from which compound 60 was identified as the most potent compound, inhibiting the development of the fourth larval (L4) stage with an IC50 of 0.01 mu M. In contrast, only 18% inhibition of the mammary epithelial cell line MCF10A viability was observed, even at concentrations as high as 50 mu M.

  DOI：

  10.1021/acs.jmedchem.8b01544

文献信息

• [EN] NOVEL TETRAZINE COMPOUNDS FOR IN VIVO IMAGING<br/>[FR] NOUVEAUX COMPOSÉS DE TÉTRAZINE POUR L'IMAGERIE IN VIVO
  申请人：UNIV COPENHAGEN

  公开号：WO2020108720A1

  公开（公告）日：2020-06-04

  The present invention relates to novel tetrazine compounds of formula I, wherein one of R1-R5 is 18F, for use in pretargeted in vivo imaging. The compounds are suitable for use in click chemistry, i.e. reactions that join a targeting molecule and a reporter molecule. The invention further relates to precursors to formula I, wherein one of R1-R5 is SnR3, B(OR)2, B(0H)2. Formula (I).

  本发明涉及一种新型四氮唑化合物，其化学式为I，其中R1-R5中的一个是18F，用于靶向体内成像。这些化合物适用于点击化学，即将靶向分子和报告分子结合的反应。该发明还涉及化合物I的前体，其中R1-R5中的一个是SnR3，B(OR)2，B(0H)2。化学式(I)。
• Synergistic Experimental and Computational Investigation of the Bioorthogonal Reactivity of Substituted Aryltetrazines
  作者：Umberto M. Battisti、Rocío García-Vázquez、Dennis Svatunek、Barbara Herrmann、Andreas Löffler、Hannes Mikula、Matthias Manfred Herth

  DOI：10.1021/acs.bioconjchem.2c00042

  日期：2022.4.20

  18F-label highly reactive tetrazines based on a 3-(3-fluorophenyl)-Tz core structure. Herein, we report a kinetic study on this versatile scaffold. A library of 40 different tetrazines was prepared, fully characterized, and investigated with an emphasis on second-order rate constants for the reaction with trans-cyclooctene (TCO). Our results reveal the effects of various substitution patterns and moreover

  四嗪 (Tz) 已被用作各种生物医学应用的生物正交剂，包括预靶向成像方法。在放射免疫成像中，预靶向增加了目标与背景的比率，同时减少了辐射负担。我们最近报道了一种基于 3-(3-氟苯基)-Tz 核心结构直接18 F-标记高反应性四嗪的策略。在此，我们报告了对这种多功能支架的动力学研究。制备、充分表征和研究了一个包含 40 种不同四嗪的库，重点是与反式反应的二级速率常数-环辛烯 (TCO)。我们的结果揭示了各种替代模式的影响，此外还证明了测量目标溶剂中反应性的重要性，因为不同溶剂中的点击率不一定具有很好的相关性。特别是，我们报告了在苯基取代基的 2 位修饰的四嗪对 TCO 表现出高固有反应性，而在水性体系中由于不利的溶剂效应而降低了反应性。所获得的结果能够预测生物正交反应性，从而有助于开发用于体内应用的下一代取代芳基四嗪。
• NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE
  申请人：Livo (Shanghai) Pharmaceutical Co., Ltd

  公开号：EP3539963A1

  公开（公告）日：2019-09-18

  Disclosed are a nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use. The nitrogen-containing heterocyclic compound of the present invention has a novel structure, relatively high TLR7 agonist activity, high selectivity and good safety.

  本发明公开了一种含氮杂环化合物、制备方法、中间体、药物组合物及用途。本发明的含氮杂环化合物结构新颖，具有较高的 TLR7 激动剂活性、高选择性和良好的安全性。
• Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use
  申请人：HEPO PHARMACEUTICAL CO., LTD.

  公开号：US11084818B2

  公开（公告）日：2021-08-10

  Disclosed are a nitrogen-containing heterocyclic compound, a preparation method thereof, an intermediate thereof, a pharmaceutical composition thereof and a use thereof. The nitrogen-containing heterocyclic compound is a compound of formula I or formula II, a tautomer thereof, an optical isomer thereof, a deuterated compound thereof, a hydrate thereof, a solvate thereof or a pharmaceutically acceptable salt thereof, which can be used for treating a disease associated with TLR7 activity. The nitrogen-containing heterocyclic compound has a relatively high TLR7 agonist activity, high selectivity and good safety.

  本发明公开了一种含氮杂环化合物、其制备方法、中间体、药物组合物及其用途。该含氮杂环化合物是式 I 或式 II 的化合物、其同分异构体、其光学异构体、其氘代化合物、其水合物、其溶液或其药学上可接受的盐，可用于治疗与 TLR7 活性相关的疾病。含氮杂环化合物具有相对较高的TLR7激动剂活性、高选择性和良好的安全性。
• [EN] NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE<br/>[FR] COMPOSÉ HÉTÉROCYCLIQUE CONTENANT DE L'AZOTE, PROCÉDÉ DE PRÉPARATION, INTERMÉDIAIRE, COMPOSITION PHARMACEUTIQUE ET UTILISATION<br/>[ZH] 含氮杂环化合物、制备方法、中间体、药物组合物和应用
  申请人：LIVO SHANGHAI PHARMACEUTICAL CO LTD

  公开号：WO2018086593A1

  公开（公告）日：2018-05-17

  本发明公开了一种含氮杂环化合物、制备方法、中间体、药物组合物和应用。本发明中的含氮杂环化合物结构新颖、具有较高的TLR7激动活性，且选择性高，安全性好。